Update on the impact of sodium-glucose cotransporter inhibitors in diabetic kidney disease progression
Introduction: Diabetic kidney disease (DKD) stands as a major cause of end-stage renal disease (ESRD). Sodium-glucose co-transporter 2 inhibitors (SGLT2i) emerged in the last years as a promising class by showing remarkable nephroprotective effects. This review focuses on the nephroprotective effect...
| Autor principal: | |
|---|---|
| Formato: | masterThesis |
| Idioma: | eng |
| Publicado em: |
2020
|
| Assuntos: | |
| Texto completo: | https://hdl.handle.net/10216/128888 |
| País: | Portugal |
| Oai: | oai:repositorio-aberto.up.pt:10216/128888 |